Royalty Pharma, Johnson & Johnson Strike $500M Autoimmune Drug Deal [Yahoo! Finance]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Yahoo! Finance
On March 30, Reuters reported that Royalty Pharma entered into a $500 million research and development agreement with Johnson & Johnson (NYSE:JNJ) to support an experimental antibody treatment for autoimmune diseases. Shares of JNJ moved up nearly 0.7% in premarket trading following the news. The agreement will run through 2026 and 2027 and focuses on the development of JNJ-4804. The therapy is designed to target IL-23 and TNF, two immune pathways that play a role in autoimmune inflammation. Royalty Pharma CEO Pablo Legorreta said the treatment shows promise for patients dealing with chronic immune-related conditions. He also pointed out that the deal builds on the company's earlier work in immunology, including investments in therapies targeting TNF. Royalty Pharma already collects royalties on more than 35 commercial products. That list includes Biogen's Tysabri and Johnson & Johnson's Tremfya, both widely used in autoimmune treatments. Johnson & Johnson (NYSE:JNJ) operates a
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- 1 Cash-Producing Stock to Own for Decades and 2 That Underwhelm [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma and J&J partner to develop autoimmune treatment [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated DiseasesGlobeNewswire
- Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma Appoints Lucas Glass as Head of Artificial IntelligenceGlobeNewswire
RPRX
Sec Filings
- 4/2/26 - Form 4
- 4/1/26 - Form 144
- 4/1/26 - Form 13F-NT
- RPRX's page on the SEC website